Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: Findings from the AURA study

British Journal of Ophthalmology

Volumn 100, Issue 12, 2016, Pages 1623-1628

  Holz, Frank G ^a   Tadayoni, Ramin ^b   Beatty, Stephen ^c   Berger, Alan ^d   Cereda, Matteo Giuseppe ^e   Hykin, Philip ^f   Staurenghi, Giovanni ^e   Wittrup Jensen, Kim ^g   Altemark, Andreas ^g   Nilsson, Jonas ^h   Kim, Kun ^h   Sivaprasad, Sobha ^f,i  

^a UNIVERSITY OF BONN   (Germany)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Institute of Eye Surgery   (Ireland)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF MILAN   (Italy)

^f MOORFIELDS EYE HOSPITAL   (United Kingdom)

^g BAYER PHARMA AG   (Germany)

^h MAPI GROUP   (Netherlands)

ⁱ KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Drugs; Macula; Retina; Treatment Medical; Vision

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CANADA; CONTROLLED STUDY; FEMALE; FRANCE; GERMANY; HUMAN; IRELAND; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; OBSERVATIONAL STUDY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; REIMBURSEMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; UNITED KINGDOM; VENEZUELA; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL NEOVASCULARIZATION; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; OPHTHALMOSCOPY; RANIBIZUMAB; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84966477831     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-308166     Document Type: Article

References (17)

1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106-16.
2. Ablonczy Z, Dahrouj M, Marneros AG. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. FASEB J 2014;28:2369-79.
3. Sharma K, Sharma NK, Anand A. Why AMD is a disease of ageing and not of development mechanisms and insights. Front Aging Neurosci 2014;6:151.
4. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 2007;39:1349-57.
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1432-44.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
7. Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122: 146-52.
8. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9.
9. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56.
10. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
11. Hariprasad SM, Morse LS, Shapiro H, et al. Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration. J Ophthalmol 2012;2012:690641.
12. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
13. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145: 239-248.
14. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9.
15. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015;99:220-6.
16. Ziemssen F, Eter N, Fauser S, et al. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Ophthalmologe 2015;112:246-54.
17. Brown DM, Tuomi L, Shapiro H. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina 2013;33:23-34.